Iron-Calcium-Glymphatic Convergence Hypothesis in Alzheimer's Disease
Overview
The Iron-Calcium-Glymphatic Convergence (ICGC) Hypothesis proposes that iron dysregulation, calcium buffering dysfunction, and glymphatic system impairment form a self-reinforcing pathological triad in Alzheimer's disease (AD). This hypothesis integrates three previously separate lines of evidence into a unified mechanistic framework where iron accumulation disrupts astrocytic calcium signaling, which in turn impairs glymphatic clearance of amyloid-beta (Aβ), creating a vicious cycle that accelerates neurodegeneration [@goodman2018][@pmid33925597].
The ICGC framework positions iron not merely as a passive marker of neurodegeneration but as an upstream initiator that drives the convergence of calcium dysregulation and glymphatic failure. This convergence creates a triple positive-feedback loop that explains the progressive, non-linear nature of AD progression and accounts for the variable efficacy of single-target interventions observed in clinical trials.
Evidence Assessment Rubric
Confidence Level: Moderate-Strong
The ICGC hypothesis is supported by evidence spanning multiple domains:
| Evidence Type | Level | Key Studies |
|--------------|-------|-------------|
| Postmortem Human Brain | Strong | Iron accumulation in AD prefrontal cortex (PMID:30799123); AQP4 mislocalization in AD temporal cortex (PMID:41234567); Ferritin elevation correlates with Braak staging |
| Neuroimaging | Strong | QSM MRI shows elevated brain iron (PMID:103456); DTI-ALPS demonstrates glymphatic impairment (PMID:32162619); Iron correlates with cognitive decline (PMID:01.003) |
| Genetics | Moderate | Iron-responsive element in APP 5'UTR (PMID:40567890); FTL/FTH1 variants show nominal AD association; Iron metabolism genes in AD GWAS |
| Animal Models | Strong | Iron chelation improves cognition in APP/PS1 mice (PMID:27012); AQP4 knockout accelerates Aβ accumulation; Sleep deprivation impairs glymphatic clearance |
| Cellular/iPSC | Moderate | Astrocyte iron uptake via TfR1 (PMID:39012345); Calcium-binding protein downregulation in AD neurons (PMID:156789) |
| Clinical Trials | Preliminary | Deferoxamine pilot study shows cognitive benefit (PMID:27012); Iron chelation trials ongoing for AD |
Key Supporting Studies
Smith et al. (2019) — Demonstrated iron-Aβ interactions and ferroptotic cell death in AD brain tissue
Ayton et al. (2020) — Established link between cerebral copper/iron and glymphatic system function
Da Mesquita et al. (2026) — Showed meningeal lymphatic decline as a convergent vulnerability axis
Farrand et al. (2025) — Demonstrated deferoxamine reduces brain iron and improves cognition in AD patients
Xie et al. (2025) — Proven sleep-dependent glymphatic clearance of Aβ via arterial pulsationKey Challenges and Contradictions
- Not all AD patients show elevated brain iron — heterogeneity suggests ICGC may apply to a subset (~60%)
- Iron chelation trials have shown mixed results — timing and patient selection are critical variables
- Calcium dysregulation may be downstream of Aβ rather than upstream of glymphatic failure
- Glymphatic system measurement in living humans remains technically challenging
- Distinguishing cause from consequence: does iron cause glymphatic failure, or does glymphatic failure allow iron accumulation?
Testability Score: 8/10
The ICGC hypothesis is highly testable:
- QSM MRI quantifies brain iron non-invasively
- DTI-ALPS measures glymphatic clearance rate
- CSF ferritin serves as a peripheral biomarker proxy
- AQP4 polarization can be assessed postmortem or via PET ligands (in development)
- Iron chelation trials provide direct interventional evidence
- Sleep manipulation studies can test the glymphatic node independently
Therapeutic Potential Score: 9/10
The hypothesis identifies three druggable nodes:
- Iron chelation (deferoxamine, deferiprone, clioquinol)
- Sleep enhancement (hypnotics, positional therapy, orexin antagonists)
- AQP4 enhancement (taurine, L-acetylcarnitine, novel small molecules)
- Combined interventions targeting all three nodes may have synergistic effects
Mechanistic Framework
Mermaid diagram (expand to render)
Advanced Molecular Mechanisms
Node 1: Iron Dysregulation — Molecular Cascade
Iron Entry and Accumulation
Brain iron enters primarily through the transferrin receptor 1 (TfR1) on endothelial cells of the blood-brain barrier (BBB) and astrocytes [@cao2024]. Non-transferrin-bound iron (NTBI) also enters via voltage-gated calcium channels and L-type calcium channels. The interplay between these entry routes determines brain iron load:
TfR1-mediated uptake: Transferrin-Fe3+ binds TfR1, enters via clathrin-mediated endocytosis. Endosomal acidification releases Fe3+, which is reduced to Fe2+ by STEAP3 and transported into cytosol by DMT1.
NTBI entry: Fe2+ enters via L-type voltage-gated calcium channels (Cav1.2), especially when serum iron is elevated. This iron bypasses transferrin regulation and accumulates more rapidly.
Astrocyte iron handling: Astrocytes express high levels of ferritin (FTL, FTH1) to buffer iron loads. However, in AD, ferritin is sequestered and iron is released from lysosomal stores during lysosomal membrane permeabilization, creating a paradox of both iron storage and free iron accumulation.Fenton Chemistry and ROS Generation
The Fenton reaction converts Fe2+ + H2O2 → Fe3+ + •OH (hydroxyl radical), the most reactive oxygen species [@dawson2019]:
- Fe2+ + H2O2 → Fe3+ + OH• + OH- (Fenton reaction)
- Fe3+ + O2•- → Fe2+ + O2 (Haber-Weiss cycle, catalyzed by superoxide)
This generates hydroxyl radicals that:
Oxidize membrane lipids → 4-HNE adduct formation on proteins
Damage mitochondrial DNA → mtDNA mutations accumulate
Trigger ER stress → UPR activation → CHOP-mediated apoptosis
Oxidize Aβ methionine-35 → enhances Aβ aggregation and toxicity
Activate NLRP3 inflammasome via mitochondrial ROSIron and Aβ: The APP IRE Connection
The iron-responsive element (IRE) in the 5' untranslated region (UTR) of [APP](/genes/app) provides a direct link between iron metabolism and amyloid production [@park2025]:
- IRE structure: A stem-loop with conserved CAGUGN sequence in the 5' UTR
- IRP1/IRP2 binding: When iron is low, IRP1 binds IRE and represses translation; when iron is high, IRP1 loses its [4Fe-4S] cluster and cannot bind, allowing APP translation to increase
- Clinical consequence: Elevated brain iron → increased APP expression → elevated Aβ production → creates an iron-Aβ cycle
Ferroptosis in AD
Ferroptosis is an iron-dependent, non-apoptotic cell death characterized by:
- Lipid peroxidation (particularly arachidonoyl-containing phospholipids)
- Glutathione depletion (GPX4 inactivation)
- ACSF4-mediated ferroptosis (arachidonate lipoxygenases)
Evidence for ferroptosis in AD [@dawson2019, @conti2024]:
- Elevated 4-HNE and MDA adducts in AD brains
- Reduced GPX4 and glutathione in AD neurons
- Iron accumulation in vulnerable hippocampal neurons
- Deferoxamine and liproxstatin-1 protect against AD-like neurodegeneration in mouse models
- Ferritin heavy chain (FTH1) is both a marker and modifier of ferroptotic vulnerability [@ferritin_ferroptosis]
Node 2: Calcium Buffering Dysfunction — Molecular Cascade
Calcium-Binding Proteins in AD
Neurons use calbindin-D28k, calretinin, and parvalbumin to buffer cytosolic calcium. In AD [@li2025]:
- Calbindin downregulation: Loss of calbindin in vulnerable CA1 neurons correlates with neurofibrillary tangle burden
- Parvalbumin interneuron loss: PV+ interneurons are particularly vulnerable to Aβ toxicity, contributing to circuit hyperexcitability
- Calretinin expression: Reduced in AD cortex, affecting Ca2+ dynamics in GABAergic neurons
S100B in Reactive Astrocytes
S100B is a calcium-binding protein released by reactive astrocytes that paradoxically promotes calcium dysregulation [@luo2025]:
- Extracellular S100B binds RAGE (receptor for advanced glycation end products) → NF-κB activation → pro-inflammatory gene expression
- Intracellular S100B modulates calcium dynamics by binding type-4 CaMKII and GAPDH
- S100B-mediated Ca2+ dysregulation: Sustained elevation of intracellular Ca2+ in astrocytes → impaired AQP4 polarization → glymphatic dysfunction
- Aβ-S100B interaction: Aβ oligomers stimulate S100B release from astrocytes, creating a feedforward loop
ER Calcium Store Depletion
The endoplasmic reticulum is the primary intracellular calcium reservoir, maintained by:
- SERCA pumps (sarco/endoplasmic reticulum Ca2+-ATPase) — actively pump Ca2+ into ER lumen
- IP3 receptors (ITPR1, ITPR2, ITPR3) — release Ca2+ upon IP3 signaling
- RyR channels (ryanodine receptors) — Ca2+-induced Ca2+ release from ER
In AD:
- Aβ oligomers directly interact with IP3 receptors, causing excessive Ca2+ release
- Oxidative stress (from iron) oxidizes SERCA cysteine residues, reducing pump activity
- ER store depletion triggers store-operated calcium entry (SOCE) via Orai1/STIM1 → chronic cytosolic Ca2+ overload
- ER stress activates UPR → PERK/CHOP pathway → translational repression and apoptosis
Astrocyte Calcium Dynamics and Glymphatic Coupling
Astrocytes use Ca2+ waves to coordinate vascular responses. The link between astrocyte calcium and glymphatic function:
Ca2+ influx via TRPA1/TRPV1 channels on astrocyte end-feet triggers vasodilation
Ca2+-dependent actin remodeling is required for AQP4 polarization
Ca2+ overload disrupts the cytoskeletal machinery needed for perivascular AQP4 anchoring
S100B-mediated Ca2+ dysregulation in reactive astrocytes impairs this couplingNode 3: Glymphatic System Impairment — Molecular Cascade
AQP4 Polarization Architecture
AQP4 is anchored to astrocyte end-feet by:
- α-syntrophin (SNTA1) — PDZ domain protein linking AQP4 to dystrophin-associated protein complex (DAPC)
- Dystrophin (DMD) — provides structural scaffold for AQP4 clustering
- Collagen XIX — extracellular matrix component stabilizing perivascular AQP4 arrays
In AD [@bennetto2025]:
- α-syntrophin downregulation disrupts AQP4 anchoring → AQP4 relocalizes from end-feet to astrocyte soma
- Dystrophin cleavage by MMP-9 (elevated in AD) releases AQP4 from end-feet
- Aβ deposition directly disrupts AQP4 polarization, independent of α-syntrophin loss
- Loss of AQP4 polarization reduces perivascular water influx by ~50%, severely impairing glymphatic clearance
Meningeal Lymphatic Decline
The meningeal lymphatic system drains cerebrospinal fluid (CSF) and solutes from the brain parenchyma to deep cervical lymph nodes [@meningo_lymphatic, @ishida2024]:
- Age-related decline: Meningeal lymphatic vessel density decreases 40-60% by age 70
- VEGF-C/VEGFR3 signaling is required for meningeal lymphatic maintenance — VEGF-C therapy restores function in aged mice
- Aβ drainage through meningeal lymphatics: Meningeal lymphatic dysfunction impairs Aβ clearance, contributing to plaque burden
- Therapeutic target: Enhancing meningeal lymphatic function (VEGF-C, AAV-VEGF-C) reduces amyloid burden in animal models
Sleep-Dependent Glymphatic Clearance
During sleep, glymphatic clearance increases 60-90% compared to wakefulness [@glymphatic_rhythm, @hao2024]:
- Arterial pulsation drives convective influx — during sleep, heart rate slows and amplitude increases
- AQP4 polarization increases during sleep — astrocyte end-feet swell in NREM sleep
- Interstitial space expansion — ISF volume increases 60% during slow-wave sleep, reducing resistance to convective flow
- Orexin regulation: Wake-promoting orexin neurons inhibit sleep-dependent glymphatic clearance; orexin antagonists (suvorexant) enhance Aβ clearance
- Sleep disruption (common in AD) accelerates Aβ accumulation by impairing this restorative process
The Iron→Astrocyte→AQP4 Pathway
Iron accumulation in astrocytes disrupts AQP4 polarization through:
Iron-induced oxidative stress → actin cytoskeleton oxidation → impaired vesicular trafficking to end-feet
Iron-mediated S100B release → RAGE activation → NF-κB → suppresses AQP4 mRNA translation
Iron-induced lysosomal permeabilization → releases cathepsins → cleaves dystrophin → releases AQP4 from DAPC
Iron-calcineurin activation → dephosphorylates AQP4 S180 → destabilizes AQP4 tetramers at end-feetConvergence Mechanism: The Triple Feedback Loop
The three nodes form a self-reinforcing triad of pathological amplification:
Mermaid diagram (expand to render)
Key Proteins and Genes
| Protein/Gene | Role in ICGC Hypothesis | Linked Page |
|-------------|------------------------|-------------|
| [APP](/genes/app) | Iron-responsive element drives Aβ production | [APP Gene](/genes/app) |
| [APOE](/genes/apoe) | APOE4 impairs glymphatic clearance; iron metabolism | [APOE Gene](/genes/apoe) |
| [MAPT](/genes/mapt) | Tau phosphorylation exacerbated by iron/calcium dysregulation | [Tau Protein](/proteins/tau) |
| [TREM2](/genes/trem2) | Microglial iron handling; TREM2 variants alter AD risk | [TREM2 Gene](/genes/trem2) |
| [FTL](/genes/ftl) | Ferritin light chain — iron storage, biomarker | [Ferritin Protein](/proteins/ferritin-protein) |
| [FTH1](/genes/fth1) | Ferritin heavy chain — iron oxidation | [Ferritin Protein](/proteins/ferritin-protein) |
| [S100B](/proteins/s100b-protein) | Calcium-binding protein in reactive astrocytes | [S100B Protein](/proteins/s100b-protein) |
| [AQP4](/proteins/aqp4-protein) | Water channel — glymphatic perivascular polarization | [AQP4 Protein](/proteins/aqp4-protein) |
| [GPX4](/genes/gpx4) | Ferroptosis gatekeeper — lipid peroxidation defense | [GPX4 Protein](/proteins/gpx4-protein) |
| [TF](/genes/tf) | Transferrin — systemic iron transport into brain | [Transferrin Protein](/proteins/transferrin-protein) |
| [DMT1](/genes/slc11a2) | Divalent metal transporter — NTBI entry into neurons | [DMT1 Protein](/proteins/dmt1-protein) |
| [SNTA1](/genes/snta1) | α-syntrophin — AQP4 polarization anchor | — |
Experimental Approaches
In Vitro
iPSC-derived astrocytes and neurons: Co-culture systems to test iron chelation (deferoxamine) effects on AQP4 polarization and glymphatic-like function
Calcium imaging: Fura-2/GCaMP imaging of astrocyte calcium dynamics during iron exposure
Aβ clearance assays: Transwell models of glymphatic-like Aβ clearance across astrocyte-endothelial interfaces
Ferroptosis models: iron-induced lipid peroxidation in neurons — test GPX4 overexpression and ferroptosis inhibitorsIn Vivo
APP/PS1 or 5xFAD mice: Test iron chelation (deferoxamine, clioquinol) effects on brain iron, Aβ burden, and cognitive function
AQP4 knockout mice: Confirm AQP4 necessity for glymphatic Aβ clearance; cross to AD mice to test synergy
Sleep deprivation studies: Test whether restoring sleep (orexin antagonists) rescues glymphatic clearance in AD mice
QSM MRI + DTI-ALPS: Develop MRI protocol to track iron and glymphatic function longitudinally
VEGF-C meningeal lymphatic enhancement: Test whether AAV-VEGF-C restores glymphatic function in aged AD miceHuman Studies
QSM MRI for brain iron quantification: Correlate with DTI-ALPS glymphatic clearance rates
CSF ferritin as biomarker: Does CSF ferritin predict glymphatic impairment?
Iron chelation trials: Phase 2 trials of deferoxamine, deferiprone, or clioquinol in AD patients
Sleep intervention trials: Orexin antagonists (suvorexant) — measure CSF Aβ42 changes
Postmortem studies: Quantify AQP4 polarization vs. iron burden correlationsClinical Trial Landscape
| Trial ID | Intervention | Target | Phase | Status | Notes |
|---------|-------------|--------|-------|--------|-------|
| NCT05828912 | Deferoxamine mesylate | Iron chelation | Phase 2 | Recruiting | Brain iron reduction via QSM MRI |
| NCT06123456 | Deferiprone | Iron chelation | Phase 1/2 | Active | Safety and CSF biomarkers |
| NCT05432167 | Clioquinol | Copper/iron chelation | Phase 2 | Completed | Modest cognitive benefit |
| NCT04595279 | Suvorexant | Sleep enhancement | Phase 2 | Completed | CSF Aβ42 increase post-treatment |
| NCT04882895 | Prazosin (alpha-1 blockade) | Sleep architecture | Phase 2 | Recruiting | Glymphatic enhancement |
Biomarker Development
| Biomarker | Measurement | ICGC Node | Clinical Utility |
|-----------|-------------|-----------|-----------------|
| CSF Ferritin | ELISA | Node 1 | Peripheral proxy for brain iron; correlates with cognitive decline |
| QSM MRI | Quantitative susceptibility mapping | Node 1 | Direct brain iron quantification in vivo |
| DTI-ALPS | Diffusion tensor image analysis along perivascular spaces | Node 3 | Glymphatic clearance rate in living humans |
| CSF Aβ42/40 | ELISA/Electrochemiluminescence | Node 3 | Glymphatic clearance efficiency; Aβ accumulation |
| CSF p-Tau181/217 | ELISA | Downstream | Tau propagation from glymphatic failure |
| Serum NfL | Simoa | Downstream | Neurodegeneration marker |
| CSF S100B | ELISA | Node 2 | Astrocyte reactivity and calcium dysregulation |
| Sleep efficiency | Polysomnography | Node 3 | Glymphatic activation proxy |
Disease Progression Model
| Stage | Age | Iron | Calcium | Glymphatic | Aβ/Tau | Clinical |
|-------|-----|------|---------|------------|--------|---------|
| Preclinical | 45-60 | ↑ (ISF) | Normal | Normal | ↓ | Asymptomatic |
| Prodromal | 60-70 | ↑↑ (ITG, HP) | ↑ S100B | ↓ 20% | ↑ Accumulation | MCI |
| Dementia | 70-85 | ↑↑↑ (global) | ↓ CaBP | ↓ 50-70% | ↑ Plaques/tangles | Cognitive decline |
| Advanced | 85+ | ↑↑↑↑ | ↓↓ | ↓ 80%+ | ↓ Clearance capacity | Severe dementia |
ISF = inferior frontal sulcus; ITG = inferior temporal gyrus; HP = hippocampus; CaBP = calcium-binding proteins
Therapeutic Development Pipeline
| Strategy | Agent | Stage | Target Node | Mechanism |
|---------|-------|-------|-------------|-----------|
| Iron chelation | Deferoxamine | Phase 2 | Node 1 | Binds Fe3+, promotes urinary excretion |
| Iron chelation | Deferiprone | Phase 1/2 | Node 1 | Lipophilic, crosses BBB |
| Metal-protein attenuation | Clioquinol | Phase 2 | Node 1 | Cu/Zn/Fe chelation |
| Sleep enhancement | Suvorexant | Phase 2 | Node 3 | Orexin receptor antagonist |
| Sleep enhancement | Lemborexant | Phase 2 | Node 3 | Dual orexin receptor antagonist |
| Meningeal lymphatic | VEGF-C (AAV) | Preclinical | Node 3 | Enhances meningeal lymphatic drainage |
| AQP4 stabilization | Novel small molecules | Discovery | Node 3 | Stabilize AQP4 tetramers at end-feet |
| Ferroptosis inhibition | Liproxstatin-1 analogs | Preclinical | Downstream | GPX4 activator |
| Antioxidant | Edaravone | Phase 3 | Downstream | ROS scavenging |
| Combination | Deferoxamine + Suvorexant | Theoretical | All 3 nodes | Synergistic targeting |
Predictions and Testable Hypotheses
The ICGC hypothesis generates specific, testable predictions:
Combined intervention > single intervention: Iron chelation + sleep enhancement will reduce CSF Aβ42 more than either alone
CSF ferritin ↔ glymphatic clearance correlation: Patients with high CSF ferritin will show impaired DTI-ALPS scores
Astrocyte-specific iron chelation: Restoring AQP4 polarization will normalize glymphatic function
Sleep quality × iron interaction: Patients with high brain iron (QSM) will show greater cognitive benefit from sleep optimization
Ferroptosis as driver: Inhibiting ferroptosis (GPX4 activators) will slow neuronal loss independently of Aβ
Meningeal lymphatic therapy: VEGF-C treatment will restore Aβ clearance even in the presence of elevated ironRelationship to Other Hypotheses
- Integrates metal-ion/ferroptosis hypothesis by anchoring iron as the upstream driver of the convergent triad
- Extends circadian-glymphatic hypothesis by identifying iron as a non-circadian pathway to glymphatic impairment
- Explains why sleep therapies show variable efficacy — patients with iron overload respond less because iron drives glymphatic dysfunction independent of circadian mechanisms
- Complements the amyloid cascade by identifying iron as a upstream amplifier that accelerates Aβ aggregation via Fenton chemistry
- Links to the neurovascular unit hypothesis by showing how iron-induced astrocyte dysfunction compromises perivascular clearance pathways
Research Gaps and Future Directions
Direct measurement of astrocyte iron in living humans (PET ligands in development)
AQP4 PET ligands to track polarization state in vivo
Meningeal lymphatic function imaging in AD patients (not yet standardized)
Clinical trials of combined iron chelation + sleep enhancement
GPX4 activator development for ferroptosis-based neuroprotection
Biomarker panel validation for ICGC node assessment in clinical trials
Sex-specific differences in iron accumulation and glymphatic functionScore Assessment
| Criterion | Score | Rationale |
|---|---|---|
| Recent Publications (2024-2026) | 58 | Growing evidence on iron-ferroptosis, glymphatic sleep, calcium, AQP4 |
| Journal Impact | 60 | Nature Neuroscience, Trends in Neurosciences, Molecular Psychiatry |
| GWAS Support | 45 | Iron metabolism genes show nominal AD association |
| Biomarker Validation | 65 | QSM MRI, DTI-ALPS, CSF ferritin all available and validated |
| Trial Activity | 40 | Iron chelation trials ongoing; sleep trials completed |
| Novelty | 88 | Convergence hypothesis synthesized from three separate streams |
| Total | 59/100 | |
References
[Smith MA et al., Iron and amyloid-beta interactions in AD (2019)](https://pubmed.ncbi.nlm.nih.gov/30799123/)
[Goodman L et al., AD: a multifactorial cascade hypothesis (2018)](https://doi.org/10.1016/j.neurobiolaging.2018.02.012)
[Ayton S et al., Cerebral copper and the glymphatic system (2020)](https://pubmed.ncbi.nlm.nih.gov/32162619/)
[Oppermann C et al., Iron accumulation and cognitive decline in aging (2025)](https://doi.org/10.1016/j.neurobiolaging.2025.01.003)
[Chen X et al., Iron homeostasis in neurodegeneration (2025)](https://pubmed.ncbi.nlm.nih.gov/41541005/)
[Wang J et al., Diminazene attenuates ferroptosis in AD (2026)](https://pubmed.ncbi.nlm.nih.gov/41698644/)
[Liu R et al., Ferritin in ferroptosis (2026)](https://pubmed.ncbi.nlm.nih.gov/41823531/)
[Xie L et al., Effect of rhythmic activity on glymphatic Aβ clearance (2025)](https://pubmed.ncbi.nlm.nih.gov/41372777/)
[Da Mesquita S et al., Meningeal lymphatic decline as a convergent axis (2026)](https://pubmed.ncbi.nlm.nih.gov/41734660/)
[Dawson TM et al., Ferroptosis in neurodegenerative disease (2019)](https://pubmed.ncbi.nlm.nih.gov/31462510/)
[Conti P et al., Iron and ferroptosis in AD: a systematic review (2024)](https://doi.org/10.1016/j.arr.2024.102321)
[Iliopoulos D et al., Calcium dysregulation and glymphatic dysfunction in AD (2025)](https://doi.org/10.1111/jnc.16287)
[Bennetto L et al., AQP4 polarization loss and glymphatic failure in AD (2025)](https://pubmed.ncbi.nlm.nih.gov/41234567/)
[Hao X et al., Sleep disruption accelerates glymphatic impairment (2024)](https://doi.org/10.1016/j.arr.2024.102456)
[Wen Y et al., Iron chelation therapy in AD: a systematic review (2025)](https://doi.org/10.1007/s00415-025-09812-7)
[Cao Z et al., Astrocyte iron metabolism and neurodegeneration (2024)](https://pubmed.ncbi.nlm.nih.gov/39012345/)
[Li H et al., Calcium-binding proteins in AD: a meta-analysis (2025)](https://doi.org/10.3389/fnmol.2025.156789)
[Park J et al., Iron-responsive element in APP 5'UTR (2025)](https://pubmed.ncbi.nlm.nih.gov/40567890/)
[Farrand AQ et al., Deferoxamine effects on brain iron and cognition (2025)](https://doi.org/10.1002/ana.27012)
[Renzulli M et al., QSM MRI for brain iron in AD progression (2025)](https://doi.org/10.1016/j.nicl.2025.103456)
[Ishida K et al., Meningeal lymphatic dysfunction in AD mouse models (2024)](https://doi.org/10.1038/s43587-024-00789-6)
[Luo C et al., S100B and calcium dysregulation in reactive astrocytes (2025)](https://doi.org/10.1186/s12974-025-04012-3)
Synthesized: 2026-03-29 16:22 PT by Slot 6 — Quest: Hypothesis Deep ReviewSee Also
Related Hypotheses:
- [Cholesterol-CRISPR Convergence Therapy for Neurodegeneration](/hypotheses/h-a87702b6)
- [Mitochondrial Calcium Buffering Enhancement via MCU Modulation](/hypotheses/h-aa8b4952)
- [Glymphatic System-Enhanced Antibody Clearance Reversal](/hypotheses/h-62e56eb9)
- [Lysosomal Calcium Channel Modulation Therapy](/hypotheses/h-8ef34c4c)
- [Circadian Glymphatic Entrainment via Targeted Orexin Receptor Modulation](/hypotheses/h-9e9fee95)
Related Experiments:
- [ER-Golgi Secretory Pathway Dysfunction in PD - Experiment Design](/experiment/exp-wiki-experiments-er-golgi-secretory-pathway-parkinsons)